Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16459234 | 0.75 | MAPT (0.35) | — | |
| SCHEMBL12461087 | 0.73 | PIK3CD (0.54) | PIK3CDNOTUMDRD2DRD3PIK3R1 | |
| SCHEMBL7952074 | 0.73 | PIK3CD (0.49) | PIK3CDNOTUMDRD2DRD3CHRNB2 | |
| SCHEMBL16459140 | 0.71 | PIK3CD (0.42) | PIK3CDNOTUMDRD2DRD3CHRNB2 | |
| SCHEMBL1366089 | 0.71 | NOTUM (0.48) | PIK3CDNOTUMDRD2DRD3PIK3R1 | |
| SCHEMBL1365674 | 0.68 | PIK3CD (0.46) | PIK3CDNOTUMPIK3R1 | |
| SCHEMBL1365252 | 0.67 | PIK3CD (0.48) | PIK3CDNOTUMPIK3R1 | |
| SCHEMBL1366893 | 0.67 | PIK3CD (0.48) | PIK3CDNOTUMPIK3R1 | |
| SCHEMBL1367657 | 0.66 | AR (0.49) | PIK3CDNOTUM | |
| SCHEMBL1367658 | 0.66 | AR (0.49) | PIK3CDNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | PIK3CD 1903/4885NOTUM 2202/4885DRD2 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.